Perinatal HIV and Option B+

Theron, Gerhard
October 2012
South African Journal of Obstetrics & Gynaecology;Oct2012, Vol. 18 Issue 3, p66
Academic Journal
An introduction is presented in which the editor discusses various reports within the issue on topics including the minimal access to antiretroviral therapy (ART), meta-analysis and systematic review of efavirenz (EFV) safety, and in vitro exposure of infants to antiretrovirals (ARVs).


Related Articles

  • partial suppressor:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p172 

    A definition of the term "partial suppressor," which refers to an individual taking highly active antiretroviral therapy whose viral load sometimes rises above the undetectable level, is presented.

  • A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings. Erlandson, Kristine M.; Taejaroenkul, Sineenart; Smeaton, Laura; Gupta, Amita; Singini, Isaac L.; Lama, Javier R.; Mngqibisa, Rosie; Firnhaber, Cynthia; Wagner Cardoso, Sandra; Kanyama, Cecilia; Machado da Silva, Andre L.; Hakim, James G.; Kumarasamy, Nagalingeswaran; Campbell, Thomas B.; Hughes, Michael D. // Open Forum Infectious Diseases;Summer2015, Vol. 2 Issue 3, p1 

    Background. Existing data on anthropomorphic changes in resource-limited settings primarily come from observational or cross-sectional studies. Data from randomized clinical trials are needed to inform treatment decisions in these areas of the world. Methods. The AIDS Clinical Trials Group...

  • Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIVinfected adults initiating HAART in South Africa. Maskew, Mhairi; Westreich, Daniel; Fox, Matthew P.; Maotoe, Thapelo; Sanne, Ian M. // Journal of the International AIDS Society;2012, Vol. 15 Issue 1, p1 

    Background: As stavudine remains an important and widely prescribed drug in resource-limited settings, the effect of a reduced dose of stavudine (from 40 mg to 30 mg) on outcomes of highly active antiretroviral therapy (HAART) remains an important public health question. Methods: We analyzed...

  • The Macroeconomic Consequences of Renouncing to Universal Access to Antiretroviral Treatment for HIV in Africa: A Micro-Simulation Model. Ventelou, Bruno; Arrighi, Yves; Greener, Robert; Lamontagne, Erik; Carrieri, Patrizia; Moatti, Jean-Paul // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Aim: Previous economic literature on the cost-effectiveness of antiretroviral treatment (ART) programs has been mainly focused on the microeconomic consequences of alternative use of resources devoted to the fight against the HIV pandemic. We rather aim at forecasting the consequences of...

  • HIV/AIDS.  // Background Notes on Countries of the World: South Africa;1/30/2012, p7 

    The article presents information on HIV rates in South Africa, as well as the country's environmental protection efforts. Having one of the highest rates of HIV prevalence in the world, South Africa implemented a 2007 to 2011 national strategic plan that provides the structure for a...

  • Patients' adherence to antiretroviral therapy at Antiretroviral Therapy sites in Limpopo Province, South Africa. LEKHULENI, M. E.; MOTHIBA, T. M.; MAPUTLE, M. S.; JALI, M. N. // African Journal for Physical, Health Education, Recreation & Dan;2013 Supplement, Vol. 19 Issue S1, p75 

    Adherence is the most important factor influencing successful antiretroviral therapy. Long term success with antiretroviral therapy (ART) requires taking 95% of medication. Less than 95% adherence can result in less than optimal therapeutic response and drug resistance. The aim of this study was...

  • highly active antiretroviral therapy (HAART):. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p108 

    An encyclopedia entry for "highly active antiretroviral therapy" is presented. This therapy refers to a powerful combination of drugs, which renders human immunodeficiency viruses undetectable in the body of an infected person. This therapy contains one drug that is usually an HIV protease...

  • Clinical trials provide the evidence critical for patient empowerment. De Cock, Kevin M; El‐Sadr, Wafaa M // Journal of the International AIDS Society;2013, Vol. 16 Issue 1, p1 

    A letter to the editor is presented in response to the article "When to start ART in Africa: primarily guided by RCTs or patient autonomy?," by Wim Delva, Yvette Fleming, and Lois Chingandu that was published in the January 2013 issue.

  • Reply to Lundgren et al. Wilkin, Timothy J.; Gulick, Roy M. // Clinical Infectious Diseases;4/15/2009, Vol. 48 Issue 8, p1162 

    A letter to the editor is presented in response to the article "Uncertainty As to Whether the Use of Antiretroviral Therapy for Persons Recently Infected With HIV Has a Favorable Risk-to-Benefit Ratio," by J. D. Lundgren, A. N. Phillips and J. Neaton in the 2009 issue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics